Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA

Clinical Pharmacokinetics

Volumn 55, Issue 4, 2016, Pages 475-483

  Wagner, Christian ^a   Pan, Yuzhuo ^a   Hsu, Vicky ^a   Sinha, Vikram ^a   Zhao, Ping ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450 3A; CYTOCHROME P450 3A INDUCER; EFAVIRENZ; ORGANIC ANION TRANSPORTER; RIFABUTIN; RIFAMPICIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); COMPUTER PROGRAM; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; MAXIMUM PLASMA CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; BIOLOGICAL MODEL; COMPUTER SIMULATION; ENZYME SPECIFICITY; FOOD AND DRUG ADMINISTRATION; SOFTWARE; UNITED STATES;

CARBAMAZEPINE; COMPUTER SIMULATION; CYTOCHROME P-450 CYP3A INDUCERS; HUMANS; MODELS, BIOLOGICAL; RIFABUTIN; RIFAMPIN; SOFTWARE; SUBSTRATE SPECIFICITY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84961158139     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-015-0330-y     Document Type: Article

References (7)

1. Zhang L, Zhang YD, Zhao P, Huang SM. Predicting drug-drug interactions: an FDA perspective. AAPS J. 2009;11:300–6.
2. Wagner C, Pan Y, Hsu V, Grillo JA, Zhang L, Reynolds KS, et al. Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug Administration. Clin Pharmacokinet. 2015;54:117–27.
3. Vieira MD, Kim MJ, Apparaju S, Sinha V, Zineh I, Huang SM, et al. PBPK Model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathways. Clin Pharmacol Ther. 2014;95:550–7.
4. Einolf HJ, Chen L, Fahmi OA, Gibson CR, Obach RS, Shebley M, et al. Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data. Clin Pharmacol Ther. 2014;95:179–88.
5. Guest EJ, Aarons L, Houston JB, Rostami-Hodjegan A, Galetin A. Critique of the twofold measure of prediction success for ratios: application for the assessment of drug–drug interactions. Drug Metab Dispos. 2011;39:170–3.
6. Xu Y, Zhou Y, Hayashi M, Shou M, Skiles GL. Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs. Drug Metab Dispos. 2011;39:1139–48.
7. Baneyx G, Parrott N, Meille C, Iliadis A, Lave T. Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration. Eur J Pharm Sci. 2014;56:1–15.